The results of the clinical trial, DAPA-CKD, which studied dapagliflozin (Farxiga) in adults with chronic kidney disease with or without type 2 diabetes on, has led the way for the FDA giving dapagliflozin breakthrough therapy designation (BTD) for adults chronic kidney disease with or without type 2 diabetes. Breakthrough therapy designation is designed to accelerate the development and regulatory review of potential new medicines that are intended to treat a serious condition and address a significant unmet medical need.
To learn more about the findings of DAPA-CKD and the newly earned BTD, please click on links below.
Please share your thoughts and subscribe to receive my blogs.
#CKD #diabetes #FDA #dapagliflozin
Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.